Merck KGaA and AstraZeneca's drug pipelines are facing market competition, with J.P. Morgan reiterating an Overweight rating.
1 report, 1 independent
Updated Sep 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Merck KGaA and AstraZeneca's drug pipelines are facing market competition, with J.P. Morgan reiterating an Overweight rating.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Merck KGaA
German multinational science and technology company